

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX, INC.
Petitioner,

v.

UCB BIOPHARMA SPRL
Patent Owner.

U.S. Patent No. 8,633,194 to Fanara *et al.*

Issue Date: January 21, 2014

Title: Pharmaceutical composition of piperazine derivatives

Inter Partes Review No.: IPR2019-00400

Petitioner's Exhibit List

Petitioner's Exhibit List

<i>Petitioner Exhibit #</i>	<i>Description</i>
1001	U.S. Patent No. 8,633,194 (“the ’194 patent”)
1002	Declaration of Dr. Laskar
1003	CV of Dr. Laskar
1004	European Patent Application Publication No. 0605203 A2 (“EP ’203”)
1005	Wang D.Y., “Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers,” <i>Allergy</i> 56 (2001), pp. 339-343 (“Wang”)
1006	Kibbe, “Handbook of Pharmaceutical Excipients,” 3rd ed. 2000 (the “Handbook”)
1007	International Patent Application No. WO 2004/050094 (“WO ’094”)
1008	Tillement, Jean-Paul <i>et al.</i> , “Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists,” <i>Biochemical Pharmacology</i> Volume 66, Issue 7, 1 October 2003, pages 1123-1126
1009	Potter, P.C., “Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites,” <i>Allergy (Oxford, United Kingdom)</i> Volume 58, Issue 9, pages 893-899, Journal 2003
1010	Gandon, J.M. <i>et al.</i> , “Lack of effect of single and repeated doses of Levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers,” <i>British Journal of Clinical Pharmacology</i> (2002), 54(1), 51-58
1011	Orange Book Entry for XYZAL
1012	R.J. Davies <i>et al.</i> , Antihistamines: topical vs. oral administration, <i>Clinical and Experimental Allergy</i> 26(3):11-17 (1996) (“Davies”)
1013	File Wrapper of ’194 patent
1014	Gennaro, A. R., Remington: The Science and Practice of Pharmacy 20th ed. (2000)
1015	U.S. Patent No. 5,698,558 to Nancy M. Grey (“US ’558”)
1016	EPO opposition
1017	Saeedi <i>et al.</i> , “The treatment of atopic dermatitis with licorice gel,” <i>Journal of Dermatological Treatment</i> (2003) 14, 1–5

1018	Duconge <i>et al.</i> , “Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds,” <i>Biopharm. Drug Dispos.</i> 25: 193–201 (2004)
1019	U.S. Patent No. 4,275,076
1020	U.S. Patent No. 5,643,584
1021	Ansel <i>et al.</i> , <i>Pharmaceutical Dosage Forms and Drug Delivery Systems</i> 7th ed. 1999
1022	Soni <i>et al.</i> , “Evaluation of the health aspects of methyl paraben: a review of the published literature,” <i>Food and Chemical Toxicology</i> 40 (2002) 1335–1373
1023	Sutton <i>et al.</i> , “Development of the Antimicrobial Effectiveness Test as USP Chapter <51>” <i>PDA Journal of Pharmaceutical Science and Technology</i> , Vol. 56, No. 6, 300-311, November/December 2002
1024	Darwish <i>et al.</i> , Effect of ethanol, propylene glycol and glycerol on the interaction of methyl and propyl <i>p</i> -hydroxybenzoate with <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> ,” <i>Int. J. of Pharm.</i> 147:51-60 (1997).